Journal article

Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years

Tomas Kalincik, Ibrahima Diouf, Sifat Sharmin, Charles Malpas, Tim Spelman, Dana Horakova, Eva Kubala Havrdova, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Vilija Jokubaitis, Anneke Van der Walt, Francois Grand'Maison, Patrizia Sola, Diana Ferraro, Vahid Shaygannejad Show all



OBJECTIVE: To test the hypothesis that immunotherapy prevents long-term disability in relapsing-remitting multiple sclerosis (MS), we modeled disability outcomes in 14,717 patients. METHODS: We studied patients from MSBase followed for ≥1 year, with ≥3 visits, ≥1 visit per year, and exposed to MS therapy, and a subset of patients with ≥15-year follow-up. Marginal structural models were used to compare the cumulative hazards of 12-month confirmed increase and decrease in disability, Expanded Disability Status Scale (EDSS) step 6, and the incidence of relapses between treated and untreated periods. Marginal structural models were continuously readjusted for patient age, sex, pregnancy, date, d..

View full abstract


Awarded by National Health and Medical Research Council of Australia

Awarded by Biogen

Funding Acknowledgements

This study was financially supported by National Health and Medical Research Council of Australia (1129189, 1140766, 1080518) and Biogen (research grant 2016003-MS). The MSBase Foundation is a not-for-profit organization that receives support from Roche, Merck, Biogen, Novartis, BayerSchering, Sanofi-Genzyme, and Teva. The study was conducted separately and apart from the guidance of the sponsors.